In silico approaches in the selection of a series of aroylhydrazones bearing melatonin moiety for neuropharmacological testing
P. Gateva , K. Ramanathan , V. Shanthi , J. Nivya
Toxicology Letters 295
2018
Safety and immunogenicity of the two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
Muhammed O Afolabi , David Ishola , Daniela Manno , Babajide Keshinro
The Lancet Infectious Diseases 22 ( 1) 110 -122
29
2022
Safety and long-term immunogenicity of the two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: A combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
David Ishola , Daniela Manno , Muhammed O Afolabi , Babajide Keshinro
The Lancet Infectious Diseases 22 ( 1) 97 -109
34
2022
Discovery of Potent Covid-19 Main Protease Inhibitors Using Machine Learning Based Virtual Screening Strategy
T MK , N James , R Karuppasamy ,
2020
Mark P. Leone & Parker B. Potter, Jr.(ed.). The recovery of meaning: Historical Archaeology in the eastern United States.
N James
Antiquity 77 ( 297) 592 -594
2003
Discovery of potent Covid-19 main protease inhibitors using integrated drug-repurposing strategy.
Ramanathan K , Nivya James , Rohini K , Muthu Kumar T
Biotechnology and Applied Biochemistry
2021
Ligand-Based Pharmacophore Screening Strategy: a Pragmatic Approach for Targeting HER Proteins.
Nivya James , K. Ramanathan
Applied Biochemistry and Biotechnology 186 ( 1) 85 -108
5
2018
Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy.
Nivya James , V. Shanthi , K. Ramanathan
Applied Biochemistry and Biotechnology 185 ( 1) 289 -315
6
2018
Density Functional Theory and Molecular Simulation Studies for Prioritizing Anaplastic Lymphoma Kinase Inhibitors.
Nivya James , V. Shanthi , K. Ramanathan
Applied Biochemistry and Biotechnology 190 ( 4) 1127 -1146
2
2020
Tackling Lung Cancer Drug Resistance Using Integrated Drug-Repurposing Strategy
Nivya James , V. Shanthi , K. Ramanathan
In Silico Drug Design 549 -575
2019
Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy
Nivya James , K. Ramanathan
Cell Biochemistry and Biophysics 76 ( 1-2) 111 -124
12
2018
Discovery of novel anaplastic lymphoma kinase inhibitors: Structure and energy-based pharmacophore strategy
Nivya James , V. Shanthi , K. Ramanathan
Journal of Theoretical and Computational Chemistry 18 ( 03) 1950014
3
2019
Exploring Novel ALK Inhibitors Using Energy Based Pharmacophore Mapping and High Throughput Virtual Screening
Nivya James , Raunaq Surana , Isha Thigale , B Preethi
Indian Journal of Pharmaceutical Education and Research 52 ( 4) 707 -717
2018
Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform
Laura-Oana Albulescu , Adam Westhorpe , Rachel H Clare , Christopher M Woodley
Frontiers in pharmacology 14 1331224 -1331224
1
2024
Discovery of anaplastic lymphoma kinase inhibitors from natural product library: A holistic in silico approach
Saranyadevi Subburaj , Tanvi Anand Nagrale , Mohd Mustufa Khan , Nivya James
Biotechnology and Applied Biochemistry 68 ( 6) 1185 -1191
1
2021
Implementation of a pipeline using disease-disease associations for computational drug repurposing
Preethi Balasundaram , Rohini Kanagavelu , Nivya James , Sayoni Maiti
Computational Methods for Drug Repurposing 129 -148
5
2019
Design of ALK Inhibitors for Non-Small Cell Lung Cancer–A Fragment Based Approach
Anika Jain , Nivya James , Veerapapillai Shanthi , Karuppasamy Ramanathan
Indian J. Pharm. Educ. Res 54 114 -124
2
2020
Small molecule therapeutics for neutralising venom toxins–a drug discovery approach
Laura Oana Albulescu , Adam Westhorpe , Amy Marriott , Rachel H Clare
Toxicon 248 21 -22
2024